
Wednesday, November 27, 2024 9:41:30 AM
Yes, management has made many mistakes but almost every small cap management team has a set of weaknesses. That's partially why you can make 5x - 10x your money. That's also why you lose sometimes too.
But I don't blame others for my failures. My fuck up. I apologize to all who counted on me.
I only focus on what to do next.
Recent OTLK News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/09/2025 09:17:49 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 07/09/2025 09:16:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/01/2025 08:31:32 PM
- Outlook Therapeutics Appoints Biopharmaceutical Industry and Commercial Leader Bob Jahr as Chief Executive Officer • GlobeNewswire Inc. • 07/01/2025 12:05:00 PM
- Outlook Therapeutics to Participate in a Virtual Investor Lunch Break Event • GlobeNewswire Inc. • 06/18/2025 01:05:00 PM
- Outlook Therapeutics® Announces SMC Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD • GlobeNewswire Inc. • 06/10/2025 12:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/02/2025 09:00:35 PM
- Outlook Therapeutics® Announces Commercial Launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK for the Treatment of Wet AMD • GlobeNewswire Inc. • 06/02/2025 11:00:00 AM
- Outlook Therapeutics® Announces Pricing of $13.0 Million Public Offering • GlobeNewswire Inc. • 05/23/2025 10:30:00 AM
- Outlook Therapeutics® Announces Proposed Public Offering of Common Stock and Warrants • GlobeNewswire Inc. • 05/22/2025 08:01:03 PM
- Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2025 and Provides Corporate Update • GlobeNewswire Inc. • 05/15/2025 08:01:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/14/2025 09:01:07 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/14/2025 09:00:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/08/2025 09:00:21 PM
- Outlook Therapeutics® Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD • GlobeNewswire Inc. • 04/08/2025 12:45:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/28/2025 08:44:04 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 03/20/2025 09:00:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/14/2025 09:00:12 PM
- Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 03/13/2025 01:11:16 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/07/2025 09:20:30 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 02/28/2025 09:37:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/28/2025 01:17:59 PM
Fifty1 AI Labs' REVIVE Clinical Trial Redefines Long COVID Treatment, Pioneering AI-Driven Therapies and Propelling Fifty 1 Labs, Inc. Toward $50M Valuation and Global Biotech Leadership • FITY • Jul 10, 2025 8:30 AM
Aspire Biopharma Holdings, Inc., Announces Positive Consumer Feedback from Company Sampling of BUZZ BOMB™, its New Sublingual Pre-Workout Supplement • ASBP • Jul 9, 2025 9:15 AM
Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers • IBRX • Jul 9, 2025 9:00 AM
Fifty 1 Labs, Inc. Announces Bold Expansion Plan Powered by Nobel Prize Laureate Management Team, Cutting-Edge AI Healthcare Innovation and $350K Leadership Investment • FITY • Jul 8, 2025 8:30 AM
Avant Technologies and Partner, Ainnova, Launch Transformative Preventative Care Model for Chronic Patients Across Latin America • AVAI • Jul 8, 2025 8:00 AM
Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs • CLDI • Jul 7, 2025 9:00 AM